Camurus Starts Phase 2b Trial of Monthly Semaglutide CAM2056 for Obesity

PUBT · 1d ago
Camurus Starts Phase 2b Trial of Monthly Semaglutide CAM2056 for Obesity
  • Camurus dosed the first patient in its Phase 2b LUNAR-2 trial of monthly semaglutide injection CAM2056 on November 3, 2026.
  • The placebo-controlled trial will enroll about 150 participants with obesity or overweight to evaluate weight loss over 36 weeks.
  • Results are expected in the first half of 2028.
  • Previously reported Phase 1b results showed faster weight loss than weekly semaglutide, with comparable safety and tolerability.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Camurus AB published the original content used to generate this news brief via Cision (Ref. ID: 202611030800BITN____UKPR__SV_20261103-BIT-4041-0) on November 03, 2026, and is solely responsible for the information contained therein.